AstraZeneca PLC ADR

Yahoo Finance • 10 hours ago

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive... Full story

Yahoo Finance • 10 hours ago

ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca” or the “Company”) (... Full story

Yahoo Finance • 18 hours ago

The Gross Law Firm Notifies Shareholders of AstraZeneca PLC (AZN) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to conta... Full story

Yahoo Finance • 2 days ago

AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman

SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating... Full story

Yahoo Finance • 4 days ago

ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN

NEW YORK, Jan. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive... Full story

Yahoo Finance • 5 days ago

AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC (“AstraZeneca... Full story

Yahoo Finance • 5 days ago

AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption – Hagens Berman

SAN FRANCISCO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a series of unsettling reports emanating... Full story

Yahoo Finance • 5 days ago

Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $200,000 in Losses to Contact the Firm

NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or the “Comp... Full story

Yahoo Finance • 5 days ago

Faruqi & Faruqi Reminds AstraZeneca Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 – AZN

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 in... Full story

Yahoo Finance • 2 months ago

AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling Claims

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China. Continue reading View comments... Full story

Yahoo Finance • 3 months ago

With 72% ownership, AstraZeneca PLC (LON:AZN) boasts of strong institutional backing

Key Insights Given the large stake in the stock by institutions, AstraZeneca's stock price might be vulnerable to their trading decisions A total of 25 investors have a majority stake in the company with 49% ownership Insiders have bought... Full story

Yahoo Finance • 4 months ago

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline

AstraZeneca Inks $1.92B License Pact With Hong Kong-Based Firm To Boost Cardiovascular Pipeline On Monday, AstraZeneca plc (NASDAQ:AZN) entered into an exclusive license agreement with Hong Kong-based CSPC Pharmaceutical Group Ltd to adva... Full story

Yahoo Finance • 4 months ago

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review

AstraZeneca Seeks Expanded Use For Blood Cancer Drug Calquence, FDA Grants Priority Review On Thursday, the FDA accepted and granted Priority Review to AstraZeneca Plc’s (NASDAQ:AZN) supplemental marketing application for Calquence (acala... Full story

Yahoo Finance • 4 months ago

Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?

We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where AstraZeneca PLC (NASDAQ:AZN) ranks among the top ten global stocks to buy. With the third quarter of 2024 ending, the discourse on the s... Full story

Yahoo Finance • 4 months ago

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst

Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst HC Wainwright initiated coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) and noted the company as an emerging biotech compa... Full story

Yahoo Finance • 4 months ago

Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

TROPION-Lung01, evaluating AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan versus chemotherapy, previously met the dual primary endpoint of progression-free survival in the overall trial population Presidential Symposium for NeoCO... Full story

Yahoo Finance • 5 months ago

AstraZeneca staff detained in China amid claims of illegal drug imports

A vial and a syringe are seen in front of a displayed AstraZeneca logo Five AstraZeneca staff have been detained in China amid claims of potential illegal activity at the British drug giant. Authorities in Shenzhen, China, are investigat... Full story

Yahoo Finance • 5 months ago

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024

Presidential Symposium will demonstrate how proprietary computational pathology biomarker for TROP2 enhances patient selection and potentially predicts patient outcomes in advanced lung cancer Presidential Symposium for NIAGARA will highl... Full story

Yahoo Finance • 5 months ago

AstraZeneca PLC (AZN): A Good 52-Week High Stock to Buy According to Short Sellers

We recently compiled a list of the 14 Best 52-Week High Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other 52-week high stocks. The U.S. sto... Full story

Yahoo Finance • 5 months ago

AstraZeneca PLC (AZN): A Cheap Pharmaceutical Stock to Buy According to Short Sellers

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other cheap pharmaceutical stocks. T... Full story